INSURANCE COVERAGE FOR SCARCE TREATMENTS: LEGAL AND REGULATORY FRAMEWORK

1. INTRODUCTION

Insurance coverage for scarce treatments refers to the legal and contractual arrangements governing reimbursement or financial protection for medical treatments that are difficult to obtain because of limited availability, high costs, specialised medical requirements, restricted production or regulatory limitations.

Scarce treatments may include rare-disease medicines, advanced cell and gene therapies, specialised biological products, organ transplantation, experimental medicines and certain life-saving procedures. These treatments frequently involve substantial financial expenditure, limited healthcare infrastructure and complicated regulatory approval requirements.

Insurance coverage becomes particularly important when patients cannot independently afford such treatments. However, insurers may refuse coverage by relying on policy exclusions, experimental-treatment restrictions, non-availability of approved providers, cost limitations or the absence of specific contractual benefits.

The central legal challenge is balancing contractual freedom, insurance risk management, medical necessity, consumer protection and the constitutional importance of access to healthcare.

2. MEANING AND SCOPE OF SCARCE TREATMENT INSURANCE

Scarce treatment insurance involves coverage for medical interventions that are not routinely available through ordinary healthcare facilities.

Major categories include:

A. RARE-DISEASE TREATMENTS

Medicines developed for uncommon genetic and metabolic disorders may be expensive and difficult to obtain because of limited production and specialised distribution requirements.

B. ADVANCED BIOTECHNOLOGY TREATMENTS

Cell therapies, gene therapies and specialised biological interventions may require specialised facilities, trained professionals and extensive medical supervision.

C. ORGAN TRANSPLANTATION

Certain transplantation procedures involve limited donor availability, specialised medical infrastructure and significant financial costs.

D. EXPERIMENTAL AND INNOVATIVE MEDICINES

Some potentially beneficial treatments remain under clinical investigation or may not yet have received the necessary regulatory approval.

E. IMPORTED MEDICAL TREATMENTS

Patients may require medicines or procedures unavailable domestically, creating additional regulatory, logistical and financial challenges.

3. FUNDAMENTAL PRINCIPLES GOVERNING INSURANCE COVERAGE

A. PRINCIPLE OF UTMOST GOOD FAITH

Insurance contracts require appropriate disclosure of material information by the parties, subject to applicable legal principles and policy terms.

B. PRINCIPLE OF INDEMNITY

In indemnity-based health insurance, compensation is generally limited by the insured loss and applicable contractual conditions. The principle must be understood alongside the specific structure of the health insurance policy.

C. MEDICAL NECESSITY

Insurers should assess whether a treatment is medically necessary by considering recognised medical evidence, professional recommendations and applicable policy conditions.

D. NON-DISCRIMINATION

Insurance decisions should not rely on arbitrary or unlawful discrimination against individuals suffering from rare or complex medical conditions.

E. TRANSPARENCY

Insurers must clearly communicate coverage limitations, exclusions, waiting periods, sub-limits and claim-rejection reasons.

4. MAJOR LEGAL ISSUES IN COVERAGE FOR SCARCE TREATMENTS

A. DENIAL OF EXPENSIVE TREATMENTS

Insurers may reject claims for expensive therapies by relying on policy exclusions or coverage limitations. However, an insurer must establish that its decision is consistent with the applicable policy wording and law.

A treatment should not automatically be considered excluded merely because it is expensive or uncommon.

B. EXPERIMENTAL TREATMENT EXCLUSIONS

Insurance policies may exclude unproven or experimental procedures. The legal issue is whether the treatment genuinely falls within the exclusion and whether the exclusion has been clearly disclosed.

C. REGULATORY APPROVAL REQUIREMENTS

Insurers may impose conditions concerning regulatory approval, authorised healthcare providers and medically recognised treatment standards.

D. IMPORTED MEDICINES AND CROSS-BORDER TREATMENT

Imported treatments create questions concerning import permissions, licensing, customs requirements, medical documentation and geographical coverage restrictions.

E. PRE-AUTHORISATION DISPUTES

Insurers may require prior approval before expensive treatment begins. Unreasonable administrative delays can become particularly serious where a patient requires urgent medical intervention.

F. SUB-LIMITS AND FINANCIAL CAPS

Policies may contain specific monetary limits for advanced therapies, transplantation or specialised medical procedures. Such restrictions must be interpreted according to their wording and applicable insurance regulations.

G. PRE-EXISTING DISEASE EXCLUSIONS

Disputes may arise when insurers classify a rare genetic or inherited condition as a pre-existing disease. The insurer's decision must be evaluated against the policy definition, disclosure requirements and applicable regulatory standards.

5. APPLICABLE LEGAL FRAMEWORK IN INDIA

A. INSURANCE ACT, 1938

Provides the principal statutory framework for insurance business in India, including regulatory requirements applicable to insurers.

B. IRDAI ACT, 1999

Establishes the Insurance Regulatory and Development Authority of India and provides the institutional framework for insurance-sector regulation.

C. IRDAI (HEALTH INSURANCE) REGULATIONS, 2024

These regulations establish important requirements concerning health insurance products, policyholder protection and regulatory oversight.

D. IRDAI (PROTECTION OF POLICYHOLDERS' INTERESTS, OPERATIONS AND ALLIED MATTERS OF INSURERS) REGULATIONS, 2024

These regulations provide important safeguards concerning policyholder interests, disclosures, servicing and claims-related obligations.

E. CONSUMER PROTECTION ACT, 2019

Provides remedies where insurance services involve deficiency in service, unfair trade practices or other legally recognised consumer violations.

F. RIGHTS OF PERSONS WITH DISABILITIES ACT, 2016

Provides protections against disability-related discrimination and supports equal participation and access to services.

G. CONSTITUTION OF INDIA – ARTICLE 21

Protects life and personal liberty. The constitutional importance of healthcare and dignity provides relevant context for evaluating access to essential medical treatment.

6. IMPORTANT JUDICIAL DECISIONS

The following judgments establish important principles concerning insurance contracts, medical treatment, consumer protection and access to healthcare. They are analogous authorities rather than direct judgments specifically determining insurance coverage for every scarce treatment.

A. LIC of India v. Consumer Education and Research Centre (1995)

The Supreme Court emphasised fairness and reasonableness in insurance arrangements involving public authorities. The decision is relevant to protecting policyholders against arbitrary and unfair insurance conditions.

B. United India Insurance Co. Ltd. v. M.K.J. Corporation (1996)

The Supreme Court discussed the principle of utmost good faith in insurance contracts. The judgment is relevant to disclosure obligations and fair treatment of insurance claims.

C. General Assurance Society Ltd. v. Chandmull Jain (1966)

The Supreme Court explained that insurance contracts must be interpreted according to their contractual terms. This decision is important when determining whether scarce treatments fall within the insured risks and exclusions.

D. Modern Insulators Ltd. v. Oriental Insurance Co. Ltd. (2000)

The Supreme Court emphasised the importance of policy terms and the communication of exclusions to the insured. This principle is relevant when insurers rely on exclusions to reject claims for specialised treatments.

E. Jacob Mathew v. State of Punjab (2005)

The Supreme Court discussed professional standards and medical negligence. Its principles are relevant when determining the appropriateness of specialised treatment recommendations and the medical evidence supporting a claim.

F. Consumer Education and Research Society v. LIC of India (1995)

The Supreme Court examined fairness in insurance-related arrangements and the constitutional relevance of reasonable treatment of policyholders. Its reasoning supports scrutiny of arbitrary insurance practices.

G. Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996)

The Supreme Court recognised that failure by government hospitals to provide timely medical treatment may violate Article 21. This judgment is relevant to the broader public-health dimension of access to scarce and life-saving treatments.

H. Spring Meadows Hospital v. Harjol Ahluwalia (1998)

The Supreme Court recognised consumer remedies in the context of deficient medical services. The judgment is relevant to disputes involving inadequate healthcare services, although it does not directly establish insurance coverage obligations.

7. PRACTICAL COMPLIANCE REQUIREMENTS

Insurance companies, healthcare institutions and policyholders should observe the following safeguards:

Clearly identify whether scarce treatments are included in the insurance policy.

Disclose exclusions relating to experimental and investigational procedures.

Establish transparent medical-necessity assessment procedures.

Provide written reasons for claim rejection.

Avoid arbitrary distinctions based solely on treatment cost.

Establish appropriate pre-authorisation procedures for specialised therapies.

Ensure timely assessment of urgent medical claims.

Maintain accurate treatment records and medical recommendations.

Clearly disclose monetary limits, sub-limits and reimbursement conditions.

Provide accessible grievance-redress mechanisms.

Ensure compliance with applicable IRDAI requirements.

Establish appropriate procedures for reviewing exceptional and complex medical claims.

8. REMEDIES AVAILABLE TO POLICYHOLDERS

Where an insurer improperly refuses coverage, policyholders may consider:

Submitting a formal representation to the insurer's grievance-redressal mechanism.

Requesting a detailed written explanation of the rejection.

Approaching the Insurance Ombudsman where the dispute falls within its jurisdiction.

Filing a complaint before the appropriate Consumer Commission.

Seeking judicial remedies in appropriate cases involving legally reviewable public-law issues.

Obtaining an independent medical opinion and preserving treatment-related documentation.

The appropriate remedy depends on the policy terms, the nature of the insurer, the disputed amount and the applicable legal requirements.

9. CONCLUSION

Insurance coverage for scarce treatments is an increasingly important issue in modern healthcare because scientific advancements have created specialised therapies that may be expensive, difficult to obtain and essential for patients suffering from serious conditions.

The legal framework must balance contractual insurance limitations with fairness, medical necessity, transparency and patient protection. Indian insurance legislation, IRDAI regulations and consumer-protection principles provide important safeguards against arbitrary claim rejection.

Judicial decisions concerning insurance fairness, contractual interpretation, medical treatment and constitutional healthcare protections provide guidance for resolving these disputes.

Ultimately, scarce treatments should be evaluated through transparent medical and contractual standards rather than rejected automatically because of their cost or limited availability. A fair insurance framework must protect legitimate insurer interests while ensuring that policyholders receive the benefits to which they are legally entitled.